Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Other hematologic neoplasm 3Myeloid 2Tumor-Agnostic 1Lymphoid 1Gastrointestinal 1

Conditions

Cholangiocarcinoma 1

Interventions

Oxaliplatin 300Fluorouracil 273Bevacizumab 238Gemcitabine 236Leucovorin 213Capecitabine 207pembrolizumab 202Irinotecan 159Nivolumab 158Cisplatin 150Specimen Handling 144Magnetic Resonance Spectroscopy 130130-nm albumin-bound paclitaxel 119Paclitaxel 109durvalumab 107Cetuximab 104Radiotherapy 99atezolizumab 94Drug Therapy 94Biopsy 93tislelizumab 81Albumin-Bound Paclitaxel 81Taxes 74Folfox protocol 68lenvatinib 67Carboplatin 66regorafenib 60Blood Specimen Collection 60sintilimab 54Ipilimumab 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
axatilimab × Gastrointestinal × 1 year × Clear all
NCT04301778 2026-03-13

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
5 enrolled 13 charts
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡